CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Oyster Point Pharma, Inc. - OYST CFD

    Market is not available at the moment

    Market information is presented
    as of 2023-09-21

    • Summary
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Oyster Point Pharma Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 11.12
    Open* 11.13
    1-Year Change* -39.18%
    Day's Range* 11.12 - 11.14
    52 wk Range 3.46-19.98
    Average Volume (10 days) 429.94K
    Average Volume (3 months) 6.72M
    Market Cap 299.85M
    P/E Ratio -100.00K
    Shares Outstanding 26.84M
    Revenue 19.58M
    EPS -6.64
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 22, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    Date Close Change Change (%) Open High Low
    Dec 30, 2022 11.14 0.00 0.00% 11.14 11.16 11.09
    Dec 29, 2022 11.12 -0.02 -0.18% 11.14 11.15 11.12
    Dec 28, 2022 11.13 0.02 0.18% 11.11 11.15 11.11
    Dec 27, 2022 11.14 0.04 0.36% 11.10 11.15 11.09
    Dec 23, 2022 11.09 0.04 0.36% 11.05 11.15 10.99
    Dec 22, 2022 11.14 0.10 0.91% 11.04 11.14 11.03
    Dec 21, 2022 11.05 -0.01 -0.09% 11.06 11.10 11.03
    Dec 20, 2022 11.04 -0.03 -0.27% 11.07 11.09 11.04
    Dec 19, 2022 11.04 -0.06 -0.54% 11.10 11.10 11.04
    Dec 16, 2022 11.09 -0.01 -0.09% 11.10 11.16 11.07
    Dec 15, 2022 11.12 0.01 0.09% 11.11 11.14 11.09
    Dec 14, 2022 11.14 0.05 0.45% 11.09 11.15 11.08
    Dec 13, 2022 11.09 0.00 0.00% 11.09 11.10 11.06
    Dec 12, 2022 11.07 -0.02 -0.18% 11.09 11.10 11.02
    Dec 9, 2022 11.09 0.00 0.00% 11.09 11.11 11.08
    Dec 8, 2022 11.08 -0.01 -0.09% 11.09 11.10 11.08
    Dec 7, 2022 11.09 0.00 0.00% 11.09 11.16 11.08
    Dec 6, 2022 11.10 0.01 0.09% 11.09 11.11 11.08
    Dec 5, 2022 11.08 -0.05 -0.45% 11.13 11.14 11.08
    Dec 2, 2022 11.09 0.00 0.00% 11.09 11.17 11.09

    Oyster Point Pharma, Inc. Events

    Time (UTC) Country Event
    Wednesday, November 8, 2023

    Time (UTC)

    21:00

    Country

    US

    Event

    Q3 2023 Oyster Point Pharma Inc Earnings Release
    Q3 2023 Oyster Point Pharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total revenue 24.539 0 0 0 0
    Total Operating Expense 121.194 70.989 47.301 16.736 6.86
    Selling/General/Admin. Expenses, Total 95.435 31.178 13.673 2.981 2.051
    Research & Development 24.234 39.811 33.628 13.755 3.632
    Unusual Expense (Income) 0 1.177
    Operating Income -96.655 -70.989 -47.301 -16.736 -6.86
    Interest Income (Expense), Net Non-Operating -3.734 0 1.59 0.233 0.259
    Net Income Before Taxes -100.659 -70.52 -45.711 -16.503 -6.601
    Net Income After Taxes -100.659 -70.52 -45.711 -16.503 -6.601
    Net Income Before Extra. Items -100.659 -70.52 -45.711 -16.503 -6.601
    Net Income -100.659 -70.52 -45.711 -16.503 -6.601
    Total Adjustments to Net Income 0 -12.543
    Income Available to Common Excl. Extra. Items -100.659 -70.52 -45.711 -16.503 -19.144
    Income Available to Common Incl. Extra. Items -100.659 -70.52 -45.711 -16.503 -19.144
    Diluted Net Income -100.659 -70.52 -45.711 -16.503 -19.144
    Diluted Weighted Average Shares 26.0365 24.1286 21.3669 20.6123 20.6123
    Diluted EPS Excluding Extraordinary Items -3.86607 -2.92267 -2.13933 -0.80064 -0.92877
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -3.86607 -2.92267 -2.13933 -0.80064 -0.87166
    Other, Net -0.27 0.469
    Revenue 24.539
    Cost of Revenue, Total 1.525
    Gross Profit 23.014
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total revenue 2.704 6.596 17.943 0 0
    Total Operating Expense 44.915 45.537 34.711 22.026 18.92
    Selling/General/Admin. Expenses, Total 39.898 38.55 28.497 15.296 13.092
    Research & Development 4.681 5.462 6.214 6.73 5.828
    Operating Income -42.211 -38.941 -16.768 -22.026 -18.92
    Other, Net -2.615 -0.513 0.222 0.01 0.011
    Net Income Before Taxes -47.892 -42.064 -17.67 -22.016 -18.909
    Net Income After Taxes -47.892 -42.064 -17.67 -22.016 -18.909
    Net Income Before Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
    Net Income -47.892 -42.064 -17.67 -22.016 -18.909
    Income Available to Common Excl. Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
    Income Available to Common Incl. Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
    Diluted Net Income -47.892 -42.064 -17.67 -22.016 -18.909
    Diluted Weighted Average Shares 26.6316 26.1929 26.038 25.9899 25.9241
    Diluted EPS Excluding Extraordinary Items -1.79832 -1.60593 -0.67862 -0.8471 -0.7294
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.79832 -1.60593 -0.67862 -0.8471 -0.7294
    Revenue 2.704 6.596 17.943
    Interest Income (Expense), Net Non-Operating -3.066 -2.61 -1.124
    Cost of Revenue, Total 0.336 1.525
    Gross Profit 2.368 5.071
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 215.25 196.367 142.18 5.618 23.174
    Cash and Short Term Investments 193.372 192.585 139.147 5.228 22.311
    Cash 5.228 22.311
    Prepaid Expenses 9.075 3.782 3.033 0.39 0.863
    Total Assets 222.617 197.91 143.209 5.704 23.174
    Property/Plant/Equipment, Total - Net 5.399 1.482 0.978 0.066 0
    Other Long Term Assets, Total 1.082 0.061 0.051 0.02 0
    Total Current Liabilities 28.802 10.982 5.399 0.94 2.067
    Accounts Payable 6.496 2.279 0.5 0.462 0.418
    Accrued Expenses 22.29 8.685 4.899 0.478 1.649
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 123.08 11.251 5.911 0.946 2.067
    Total Long Term Debt 89.819 0.019 0 0 0
    Other Liabilities, Total 4.459 0.25 0.512 0.006 0
    Total Equity 99.537 186.659 137.298 4.758 21.107
    Redeemable Preferred Stock 0 0 0
    Preferred Stock - Non Redeemable, Net 0 43.001 43.001
    Common Stock 0.027 0.026 0.021 0.004 0.004
    Additional Paid-In Capital 354.92 341.384 221.508 0.273 0.119
    Retained Earnings (Accumulated Deficit) -255.41 -154.751 -84.231 -38.52 -22.017
    Total Liabilities & Shareholders’ Equity 222.617 197.91 143.209 5.704 23.174
    Total Common Shares Outstanding 26.5796 25.8905 21.3669 20.6123 20.6123
    Cash & Equivalents 193.372 192.585 139.147
    Property/Plant/Equipment, Total - Gross 5.636 1.578 0.997
    Accumulated Depreciation, Total -0.237 -0.096 -0.019
    Current Port. of LT Debt/Capital Leases 0.016 0.018
    Capital Lease Obligations 0.004 0.019
    Total Receivables, Net 6.656
    Accounts Receivable - Trade, Net 6.656
    Total Inventory 6.086
    Other Current Assets, Total 0.061
    Long Term Investments 0.886
    Long Term Debt 89.815
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 167.354 215.25 189.686 158.886 182.648
    Cash and Short Term Investments 143.364 193.372 184.166 154.805 175.91
    Cash & Equivalents 143.364 193.372 184.166 154.805 175.91
    Prepaid Expenses 14.099 9.075 3.02 4.081 6.738
    Total Assets 176.72 222.617 195.009 161.503 184.772
    Property/Plant/Equipment, Total - Net 5.257 5.399 2.627 2.526 2.033
    Other Long Term Assets, Total 3.223 1.082 2.696 0.091 0.091
    Total Current Liabilities 23.026 28.802 15.161 9.471 13.736
    Accounts Payable 2.596 6.496 3.506 2.332 7.093
    Accrued Expenses 20.399 22.29 11.638 7.121 6.625
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.031 0.016 0.017 0.018 0.018
    Total Liabilities 120.727 123.08 57.497 9.719 14.124
    Total Long Term Debt 90.666 89.819 41.926 0.011 0.015
    Capital Lease Obligations 0.03 0.004 0.007 0.011 0.015
    Other Liabilities, Total 7.035 4.459 0.41 0.237 0.373
    Total Equity 55.993 99.537 137.512 151.784 170.648
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.027 0.027 0.026 0.026 0.026
    Additional Paid-In Capital 359.268 354.92 350.832 347.434 344.282
    Retained Earnings (Accumulated Deficit) -303.302 -255.41 -213.346 -195.676 -173.66
    Total Liabilities & Shareholders’ Equity 176.72 222.617 195.009 161.503 184.772
    Total Common Shares Outstanding 26.6627 26.5796 26.0942 26.0064 25.9608
    Total Receivables, Net 5.736 6.656 2.5
    Long Term Debt 90.636 89.815 41.919
    Accounts Receivable - Trade, Net 5.736 6.656
    Total Inventory 4.094 6.086
    Other Current Assets, Total 0.061 0.061
    Long Term Investments 0.886 0.886
    Property/Plant/Equipment, Total - Gross 5.568
    Accumulated Depreciation, Total -0.311
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line -100.659 -70.52 -45.711 -16.503 -6.601
    Cash From Operating Activities -89.37 -58.399 -40.815 -17.083 -4.674
    Non-Cash Items 13.639 6.973 3.266 0.154 1.081
    Changes in Working Capital -2.491 5.071 1.611 -0.734 0.846
    Cash From Investing Activities -1.485 -0.7 -0.2 0 0
    Capital Expenditures -1.485 -0.7 -0.2 0 0
    Cash From Financing Activities 91.642 112.547 174.985 0 26.175
    Financing Cash Flow Items -4.947 -0.361 0 0
    Issuance (Retirement) of Stock, Net 96.589 112.908 174.985 0 21.875
    Issuance (Retirement) of Debt, Net 0 4.3
    Net Change in Cash 0.787 53.448 133.97 -17.083 21.501
    Cash From Operating Activities 0.141 0.077 0.019
    Cash Interest Paid 2.352
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -47.892 -100.659 -58.595 -40.925 -18.909
    Cash From Operating Activities -49.705 -89.37 -47.895 -37.085 -16.53
    Cash From Operating Activities 0.074 0.141 0.091 0.055 0.023
    Non-Cash Items 8.222 13.639 8.696 5.728 2.68
    Changes in Working Capital -10.109 -2.491 1.913 -1.943 -0.324
    Cash From Investing Activities -0.085 -1.485 -1.25 -0.994 -0.34
    Capital Expenditures -0.085 -1.485 -1.25 -0.994 -0.34
    Cash From Financing Activities -0.218 91.642 40.726 0.299 0.195
    Financing Cash Flow Items -0.087 -4.947 -0.03 -0.023 -0.023
    Issuance (Retirement) of Stock, Net 0.076 96.589 0.605 0.322 0.218
    Net Change in Cash -50.008 0.787 -8.419 -37.78 -16.675
    Issuance (Retirement) of Debt, Net -0.207 40.151
    Cash Interest Paid 2.067 2.352

    Oyster Point Pharma, Inc. Company profile

    About Oyster Point Pharma Inc

    Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Oyster Point Pharma Inc revenues increased from $0K to $24.5M. Net loss increased 43% to $100.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase of 33% to $33.5M (expense), Stock-based Compensation in SGA increase of 22% to $7.3M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    202 Carnegie Center
    Suite 106
    PRINCETON
    NEW JERSEY 08540
    US

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    BTC/USD

    26,680.30 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    89.95 Price
    +0.690% 1D Chg, %
    Long position overnight fee 0.0349%
    Short position overnight fee -0.0568%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,596.06 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    XRP/USD

    0.52 Price
    +0.670% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading